Inventurus Knowledge Solutions Ltd. Share Price

Inventurus Knowledge Solutions Ltd on different parameters

Quality :- Inventurus Knowledge Solutions Ltd continues to demonstrate robust fundamental strength, underscored by an excellent quality profile. The company’s long-term operational efficiency is evident in its average Return on Capital Employed (ROCE) of 31.76%, signalling effective utilisation of capital resources. This is complemented by a consistent growth trajectory, with net sales expanding at an annual rate of 32.50% and operating profit advancing at 44.73% over the long term. Such figures indicate a solid business model capable of sustaining growth while maintaining profitability. Valuation :- The valuation aspect of Inventurus Knowledge Solutions Ltd remains a focal point in the recent evaluation revision. The company is currently assessed as very expensive relative to typical benchmarks within the Computers - Software & Consulting sector. This elevated valuation reflects market expectations of sustained growth and profitability, but also introduces a degree of caution given the premium pricing. Investors and analysts alike may be weighing the balance between the company’s strong fundamentals and the cost of entry at current price levels. Financial Trend:- Financially, the company exhibits a positive trend, supported by a series of encouraging quarterly results. Inventurus Knowledge Solutions Ltd has reported positive earnings for six consecutive quarters, with the latest six-month Profit After Tax (PAT) reaching ₹399.71 crores and growing at a rate of 33.53%. Technical :-technical perspective, the stock maintains a bullish stance, supported by recent price movements and market sentiment. Over the past six months, the stock has delivered a notable return of 39.67%, significantly outperforming the broader market indices. Year-to-date returns stand at 11.18%, while the one-year return is recorded at 23.01%, contrasting favourably against the BSE500 index, which has experienced a negative return of -3.04% over the same period.

See More

HBL Engineering Recent setup: broke out candidate

HBL Engineering Recent setup: broke out of a consolidation range and trendline with strong volume. Reference price: ₹775.30 Upside levels cited by JM Financial: ₹809 and ₹830 Risk level cited: ₹735 The broader market was weak on Sept 24, so a breakout should ideally be confirmed by volume rather than chased at the open. Other current breakout/momentum setups worth watching: Inventurus Knowledge Solutions: ₹1,868 → ₹2,050/₹2,150; SL ₹1,785. Alembic Pharma: ₹850 → ₹900/₹999; SL ₹786. Finolex Cables: ₹1,480 → ₹1,600; SL ₹1,400. Important: These are technical setups reported by analysts, not a guaranteed “tomorrow breakout.” For Monday, I'd wait for the first 15–30 minutes and look for price + volume confirmation.

See More

Inventurus Knowledge Solutions Ltd – Bullish Breakout Setup

The stock is showing fresh buying interest after a prolonged consolidation, with a strong bullish candle indicating possible trend continuation. 🔎 Technical Observations: • Consolidation within a triangle pattern • Strong bullish breakout candle with volume • Price reclaiming key resistance levels • Support holding near ₹1760–1800 • Momentum indicators turning positive 🔑 Key Levels to Watch: • Immediate Support: ₹1852 – ₹1800 • Major Support: ₹1760 – ₹1686 • Immediate Resistance: ₹1963 – ₹2018 🚀 Upside Targets: • ₹1963 • ₹2018 • ₹2073 • ₹2128+ 📉 Risk Scenario: Breakdown below ₹1800 may weaken the setup and lead to further consolidation towards ₹1760–1686. 📈 Trading View: 👉 Bullish breakout from the consolidation zone 👉 Sustained move above ₹1963 can trigger fresh upside momentum 👉 Breakout above ₹2018 may open the way towards higher targets ⚠️ For educational purposes only. Not a buy/sell recommendation. — AALGO BREATHS 📊

See More

Inventurus: Inverse H&S Plays Out to the Target

gained nearly 5% in a single session, moving from the neckline breakout of its Inverse Head & Shoulders pattern near 1,780 toward the measured-move target of 80 points (4.52%) projected from the Head-to-neckline distance, with the stock settling near 1,875. This is a clean instance of a classical pattern completing close to its textbook projection, with RSI at 74.04 reflecting the strength of the follow-through move. Whether price consolidates near the projected target or extends further will be worth watching, as measured-move levels often act as a natural zone for profit booking after such a sharp move. A slip back below the neckline zone would be the level to note if the move starts to lose steam. A measured-move target being reached this precisely is a good reminder of why classical patterns remain widely tracked — though a target zone often becomes a pause point, not just a stop. Disclaimer:This is for educational purposes only and is not investment advice. Please consult your financial advisor before making any investment decisions. SEBI Registered Research Analyst — INH000025212.

See More

IKS Health: 33% Margins, 5M Records – India's Hidden Healthcare Tech Gem

Inventurus Knowledge Solutions is a healthcare technology company serving US health systems with revenue cycle management, clinical support and value-based care solutions. Managing 5+ million patient records, IKS combines 20%+ growth with ~33% EBITDA margins, offering compelling exposure to India’s healthcare IT export story. IKS uses an asset-light, technology-enabled services model to help US hospitals and physician groups improve billing, collections and clinical workflows. In Q1 FY27 (June 2026), revenue rose 21% YoY to ₹8,936 million, EBITDA reached ₹2,949 million (33% margin) and PAT was ₹1,937 million (21.7% margin). Adjusted PAT, excluding one-time acquisition costs, grew 28% to ₹2,153 million. FY26 revenue increased 20% to ₹31,938 million, while PAT grew 48%, demonstrating strong operating leverage. ROE of 26–40% and Q1 FY27 free cash flow of ₹1,742 million (+27% YoY) highlight strong capital efficiency and cash generation. High margins: 33–35% EBITDA margins indicate strong operational efficiency and pricing power. Growth at scale: 20%+ revenue growth alongside rising profits suggests limited growth-versus-margin trade-off. Strong cash generation: Supports reinvestment, acquisitions, debt reduction and potential shareholder returns. High ROE: 26–40% ROE comfortably exceeds the cost of equity, creating economic value. At ~44x P/E (August 2026), the stock commands a premium valuation and requires sustained high growth. USD/INR movements affect reported performance; Q1 constant-currency growth was 12% versus 21% in rupee terms. Acquisition-related costs, including TruBridge, can temporarily affect margins. IKS Health is a high-quality, high-margin growth company. Sustained 20%+ growth, 33%+ EBITDA margins and 25%+ ROE make it attractive for long-term shareholders. The key risk is valuation compression if growth or margins disappoint.

See More